皮肌炎胃肠道受累:多中心回顾性队列研究
该研究评估皮肌炎(DM)患者胃肠道(GI)受累的患病率,并描述抗NXP2抗体阳性DM的特征。在单中心DM队列(n=119)中,抗NXP2患者严重GI受累占18%,抗MDA5患者占6%;抗NXP2患者严重GI受累风险显著高于其他DM亚组(HR 8.85,95%CI 1.62-48.35)。在多中心抗NXP2队列(n=48)中,严重GI受累发生率为12.5%,且与年轻和颜面水肿相关。
要点
- 严重GI受累在抗NXP2阳性DM患者中发生率为18%,显著高于其他亚组。
- 多中心抗NXP2队列中严重GI受累发生率为12.5%,包括消化道穿孔和出血。
- 抗NXP2患者严重GI受累与年轻(中位24.5 vs 42.5岁)和颜面水肿(83% vs 33%)相关。
核心结论
- 严重GI受累是DM的危及生命的并发症,主要与抗NXP2抗体相关。
- 在抗NXP2 DM中,年轻年龄和颜面水肿与严重GI受累相关。
研究设计与样本
- 回顾性单中心DM队列(n=119)评估GI受累患病率。
- 回顾性多中心抗NXP2 DM队列(n=48)进一步研究。
- GI受累定义为任何症状性GI病变(排除孤立性吞咽困难),严重定义为需手术和/或ICU入住。
主要发现
- 单中心队列中,严重GI受累在抗NXP2患者占18%,抗MDA5患者占6%。
- 抗NXP2患者严重GI受累风险显著高于其他DM亚组(HR 8.85,95%CI 1.62-48.35)。
- 多中心抗NXP2队列中,严重GI受累发生率为12.5%(包括4例消化道穿孔和3例消化道出血)。
- 抗NXP2患者中,严重GI受累者中位年龄24.5岁 vs 42.5岁(P<0.01),颜面水肿83% vs 33%(P=0.03)。
- GI受累时,78%的抗NXP2患者有 concomitant 皮肤和/或肌肉疾病活动。
关键数值与推荐
- 严重GI受累定义:需手术和/或ICU入住。
- 抗NXP2患者严重GI受累发生率18%(单中心队列)。
- 抗NXP2患者严重GI受累风险HR 8.85(95%CI 1.62-48.35)。
- 多中心抗NXP2队列严重GI受累发生率12.5%(n=48)。
- 年龄中位数24.5 vs 42.5岁(P<0.01)和颜面水肿83% vs 33%(P=0.03)与严重GI受累相关。
临床怎么用
- 对DM患者应警惕GI受累,尤其抗NXP2抗体阳性者。
- 抗NXP2阳性DM患者若年轻且伴颜面水肿,需加强GI严重并发症监测。
- GI受累时多数患者有皮肤和/或肌肉疾病活动,提示需整体评估病情。
局限性
- 研究为回顾性设计,可能存在选择偏倚和信息偏倚。
- 样本量较小(单中心n=119,多中心n=48),结论需更大样本验证。
- 未报告死亡率,但研究期间无死亡报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gastrointestinal (GI) involvement in myositis is a severe extra muscular manifestation with potentially life-threatening outcomes. However, it remains poorly characterized. We aimed to evaluate the prevalence of GI involvement in DM and to describe its characteristics in anti-nuclear matrix protein-2 (NXP2) DM. METHODS: The prevalence of GI involvement across DM subgroups was assessed in a retrospective monocentric DM cohort (n = 119). It was further investigated in a retrospective multicentric cohort of anti-NXP2 DM (n = 48). GI involvement (defined as any symptomatic GI lesion, excluding isolated dysphagia) was considered severe when requiring surgery and/or intensive care unit admission. RESULTS: In the monocentric DM cohort, severe GI involvement was observed in 18% of anti-NXP2 patients and 6% of anti-melanoma differentiation-associated protein 5 (MDA5) patients. Severe GI involvement was significantly more frequent in anti-NXP2 patients compared with other DM subgroups [hazard ratio 8.85 (95% CI 1.62-48.35)]. In the multicentric anti-NXP2 cohort, severe GI involvement (including four digestive perforations and three digestive haemorrhages) occurred in 12.5% of patients. Anti-NXP2 patients with severe GI involvement were significantly younger (median age 24.5 vs 42.5 years; P < 0.01) and more frequently presented with facial oedema at diagnosis (83% vs 33%; P = 0.03). At the time of GI involvement, 78% of anti-NXP2 patients had concomitant skin and/or muscle disease activity. No deaths were reported. CONCLUSION: Severe GI involvement represents a life-threatening complication in DM and is mainly associated with anti-NXP2 antibody. In anti-NXP2 DM, young age and facial oedema are associated with severe GI involvement.
引用
- Demuynck O, Rasmussen C, Khitri MY, et al. Gastrointestinal involvement in dermatomyositis: multicentric retrospective cohort study. Rheumatology (Oxford). 2026. PMID: 42308536. doi:10.1093/rheumatology/keag282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。